New York, NY, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Retinal Biologics Market By Drug Class (TNF-a Inhibitor and VEGF-A Antagonist), By Indication (Diabetic Retinopathy, Macular Degeneration, Uveitis, Diabetic Macular Edema, and Others), and by Distribution Channel (Retail Sales and Institutional Sales): Global Market Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global retinal biologics market was USD 13,082 million in 2018 and is expected to generate around USD 28,015 million by 2025, at a CAGR of 11.5% between 2019 and 2025.
The retina is a sensitive and delicate part of the human eye, which receives and processes light and converts it into neural signals and forwards them to the brain for performing visual activities. Retinal disorders include macular degeneration related to age, infectious retinitis, macular edema, diabetic retinopathy, macular hole, retinoblastoma, retinal degeneration, uveitis, and retinoschisis.
Browse through 54 Tables & 21 Figures spread over 120 Pages and in-depth TOC on “Global Retinal Biologics Market: By Type, Drug Class, Industry Size, Share, Applications, Trends, Analysis and Forecast, 2018–2025”.
Request Free Sample Report of Global Retinal Biologics Market @ https://www.zionmarketresearch.com/sample/retinal-biologics-market
The worldwide escalation of ophthalmic disorders, due to aging, is the prime factor driving the retinal biologics market globally. The development of several new products in the form of drug-releasing implants and biologics due to the consistent efforts for developing better treatment options are further propelling the market for retinal biologics. However, the limited availability of the biologics, adverse effects of biologics, and strict regulatory requirements associated with biologics approval may hamper the market for retinal biologics in the future.
The retinal biologics market is fragmented based on drug class, indication, and distribution channel. By drug class, the market includes TNF-α inhibitor and VEGF-An antagonist. The TNF-α inhibitor is expected to register a higher CAGR in the retinal biologics market over the forecast time period. The VEGF-A antagonist accounted for the largest share in the global market in 2018, as VEGF-A antagonist is widely available in the market for treating retinal disorders.
Request for PDF Brochure of This Report: https://www.zionmarketresearch.com/requestbrochure/retinal-biologics-market
On the basis of indication, the retinal biologics market comprises diabetic macular edema, macular degeneration, diabetic retinopathy, uveitis, and others. The macular degeneration accounted for the largest share in the retinal biologic market in 2018, as macular degeneration (MD), is among the major causes of vision loss. Diabetic macular edema and diabetic retinopathy accounted for significant shares in the global market. Growing incidences of diabetes complications and the rising diabetes epidemic will continue to boost the growth of these segments.
The distribution channel segment includes retail sales and institutional sales. The retail sales segment includes mail order and retail pharmacies. The institutional sales segment is bifurcated into specialty clinics and hospitals. The institutional sales segment accounted for the largest share in the retinal biologics market in 2018. In institutional sales, the specialty clinics accounted for the larger market share.
Browse the full “Retinal Biologics Market By Drug Class (TNF-a Inhibitor and VEGF-A Antagonist), By Indication (Diabetic Retinopathy, Macular Degeneration, Uveitis, Diabetic Macular Edema, and Others), and by Distribution Channel (Retail Sales and Institutional Sales): Global Market Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/retinal-biologics-market
North America accounted for the largest share in the retinal biologics market globally, due to the growing retinal disorders prevalence, favorable reimbursement scenario, and easy availability of biologics. Diabetic retinopathy is the leading cause of visual loss among Americans. Diabetic people are at almost risk to suffer from diabetic retinopathy. According to the WHO, in October 2017, about 253 million people suffered from vision impairment. Among the 253 million, about 217 million people had moderate to chronic vision impairment and 36 million were blind. About 81% of the people with severe or moderate vision impairment or blind were aged over 50 years. According to Vision Problems, in the U.S. 2012, the overall prevalence of diabetic retinopathy is 5.4% in the U.S. for people aged 40 and above. Moreover, the presence of a significant number of ophthalmologists in the U.S. is also contributing to the North American retinal biologics market. According to the American Academy of Ophthalmology, about 19,216 active ophthalmologists were recorded in 2014, and about 213,459 ophthalmologists globally.
Europe accounted for the second spot in the retinal biologics market in 2018 globally, due to the high demand for biologics, particularly from western European countries like the U.K., Germany, and Italy.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/retinal-biologics-market
The Asia Pacific is expected to register the highest CAGR in the retinal biologics market globally, owing to the increasing adoption of technically-advanced drugs and large patient pool suffering from retinal disorders. Moreover, improvements in healthcare infrastructure, a growing number of untreated eye diseases, rising government support to avail the diagnosis and treatment of retinal disorders and increasing awareness about retinal disorders are also propelling this regional market.
Latin America and the Middle East and Africa are potential markets for retinal biologics, owing to the rapid expansion of the healthcare industry along with the increasing adoption of advanced therapeutics.
Some key players of the retinal biologics market are Janssen Biotech, Alimera Sciences, F. Hoffmann-La Roche, Ocular Therapeutix, Genzyme Corporation, UCBCares, AbbVie, Allergan, Swedish Orphan Biovitrum, Genentech, Bristol-Myers Squibb, and Bausch & Lomb.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/4744
This report segments the global retinal biologics market into:
Global Retinal Biologics Market: Drug Class Analysis
- TNF-α Inhibitor
- VEGF-A Antagonist
Global Retinal Biologics Market: Indication Analysis
- Diabetic Retinopathy
- Macular Degeneration
- Uveitis
- Diabetic Macular Edema
- Others
Global Retinal Biologics Market: Distribution Channel Analysis
- Retail Sales
- Mail Order Pharmacies
- Retail Pharmacies
- Institutional Sales
- Hospitals
- Specialty Clinics
Global Retinal Biologics Market: Regional Analysis
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- The Middle East and Africa
Related Reports:
- Cellulite Treatment Market: https://www.zionmarketresearch.com/report/cellulite-treatment-market
- Pediatric Vaccine Market: https://www.zionmarketresearch.com/report/pediatric-vaccine-market
- Peptide and Anticoagulant Drugs Market: https://www.zionmarketresearch.com/report/peptide-anticoagulant-drugs-market
- Allergy Immunotherapy Market: https://www.zionmarketresearch.com/report/allergy-immunotherapy-market
- Intravenous Immunoglobulin Market: https://www.zionmarketresearch.com/report/intravenous-immunoglobulin-ivig-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
Contact Us:
Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com
Blog: http://newszmr.com